Eon™ FR 1064 Full Abdomen Clinical Study Protocol

Inclusion Criteria: * Subject is a healthy male or female \> 18 years or older seeking treatment for unwanted fat in the abdomen. * Subject must be able to read, understand and sign the Informed Consent Form (ICF) in English. * Subject has sufficient thickness (≥ 25 mm) of adipose tissue on the abdomen area. * Study subjects must agree to maintain their current diet and weight (not gaining or losing greater than ±5 lbs. * Subject must be willing and able to adhere to the treatment and follow-up visit schedule. * Subject must be willing to have limited sun exposure for the duration of the study, including the follow-up period. * Subject is willing to have photographs and ultrasound measurements taken of the treated area, which will be de-identified in evaluations and may be used in presentations and/or publications. * Female subjects must be using medically acceptable form of birth control during the entire course of the study or may be post-menopausal, surgically sterilized. Exclusion Criteria: * Aesthetic fat reduction procedure in the treatment area within the previous year. * Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in last 6 months * Unstable weight within the last 6 months (+ or - 3% weight change in the prior six months) * Subject has an infection, dermatitis or a rash in the treatment area. * Subject has tattoos or jewelry in the treatment area or within the treatment area site or photography frame. * Subject has a history of keloid scarring, hypertrophic scarring or of abnormal wound healing. * Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. * Subject has a history of a known bleeding disorder. * Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light. * Subject has known collagen, vascular disease or scleroderma. * Subject has undergone a surgery or procedure in the treatment area within 6 months of treatment, which is still healing. * Subject suffers from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy. * Subject is undergoing systemic chemotherapy for the treatment of cancer. * Subject is using gold therapy for disorders such as rheumatologic disease or lupus. * Subject has participated in a study of another device or drug within three months prior to enrollment or during the study. * As per the investigator's discretion, the subject has any physical or mental condition which might make it unsafe for the subject to participate in this study. * Subject has ongoing use of steroids or secondary rheumatoid drugs. * Subject is actively taking psychotropic medications.